Stock Scorecard



Stock Summary for Nektar Therapeutics (NKTR) - $8.61 as of 6/18/2025 8:42:17 PM EST

Total Score

12 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for NKTR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for NKTR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for NKTR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for NKTR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for NKTR (22 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for NKTR

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down 5/9/2025 1:08:00 PM
Nektar Therapeutics ( NKTR ) Reports Q1 Loss, Lags Revenue Estimates 5/8/2025 10:25:00 PM
Will Nektar Therapeutics ( NKTR ) Report Negative Q1 Earnings? What You Should Know 5/1/2025 2:01:00 PM
Why Is Nektar ( NKTR ) Down 38.8% Since Last Earnings Report? 4/11/2025 3:30:00 PM
Nektar Therapeutics ( NKTR ) Q4 Earnings Miss Estimates ( Revised ) 3/14/2025 11:33:00 AM
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up 3/13/2025 4:15:00 PM
Nektar Therapeutics ( NKTR ) Q4 Earnings Beat Estimates 3/12/2025 11:00:00 PM
Assertio ( ASRT ) Reports Q4 Loss, Tops Revenue Estimates 3/12/2025 9:20:00 PM
Recursion Pharmaceuticals ( RXRX ) Reports Q4 Loss, Lags Revenue Estimates 2/28/2025 12:40:00 PM
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus - Nektar Therapeutics ( NASDAQ:NKTR ) 2/24/2025 12:00:00 PM

Financial Details for NKTR

Company Overview

Ticker NKTR
Company Name Nektar Therapeutics
Country USA
Description Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 8.61
Price 4 Years Ago 202.65
Last Day Price Updated 6/18/2025 8:42:17 PM EST
Last Day Volume 449,262
Average Daily Volume 1,773,813
52-Week High 22.79
52-Week Low 6.48
Last Price to 52 Week Low 32.87%

Valuation Measures

Trailing PE N/A
Industry PE 22.38
Sector PE 40.20
5-Year Average PE -31.39
Free Cash Flow Ratio 2.75
Industry Free Cash Flow Ratio 17.66
Sector Free Cash Flow Ratio 31.91
Current Ratio Most Recent Quarter 3.24
Total Cash Per Share 3.13
Book Value Per Share Most Recent Quarter 1.11
Price to Book Ratio 7.76
Industry Price to Book Ratio 34.50
Sector Price to Book Ratio 30.01
Price to Sales Ratio Twelve Trailing Months 1.32
Industry Price to Sales Ratio Twelve Trailing Months 122.91
Sector Price to Sales Ratio Twelve Trailing Months 34.69
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 12,406,900
Market Capitalization 106,823,409
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 9.72%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 56.91%
Reported EPS 12 Trailing Months -10.18
Reported EPS Past Year -0.24
Reported EPS Prior Year -0.77
Net Income Twelve Trailing Months -133,041,000
Net Income Past Year -118,961,000
Net Income Prior Year -276,056,000
Quarterly Revenue Growth YOY -51.70%
5-Year Revenue Growth -3.00%
Operating Margin Twelve Trailing Months -424.20%

Balance Sheet

Total Cash Most Recent Quarter 38,894,000
Total Cash Past Year 44,252,000
Total Cash Prior Year 35,277,000
Net Cash Position Most Recent Quarter 38,894,000
Net Cash Position Past Year 44,252,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 250,000,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 60,737,000
Total Stockholder Equity Prior Year 130,987,000
Total Stockholder Equity Most Recent Quarter 13,738,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -178,187,000
Free Cash Flow Per Share Twelve Trailing Months -14.36
Free Cash Flow Past Year -177,177,000
Free Cash Flow Prior Year -193,471,000

Options

Put/Call Ratio 0.37
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.04
MACD Signal 0.04
20-Day Bollinger Lower Band 7.47
20-Day Bollinger Middle Band 11.15
20-Day Bollinger Upper Band 14.84
Beta 0.56
RSI 45.78
50-Day SMA 15.47
150-Day SMA 21.01
200-Day SMA 52.80

System

Modified 6/17/2025 6:09:24 AM EST